GPCRs: Uncovering Novel Targets for Drug Discovery

European GPCR Technology Symposium Presented by DiscoverX and GDR-3545

Date: April 12, 2016
Time: 09:00 AM – 5:00 PM
Location: The MacGrath Lecture Theatre, St. Catherine’s College, Cambridge, CB2 1RL

This is a FREE symposium!

View the program and register here

 

Symposium Program

The Apelin and Elabela/Toddler Receptor as Novel Target in Cardiovascular Disease
Anthony Davenport, University of Cambridge

Exploring GPCR Activation in Immunometabolism and Inflammation
David R. Greaves, Professor of Inflammation Biology, University of Oxford

Fluorescent Probes to Track GPCR Binding and Dimerization
Dominique Bonnet, CNRS researcher, University of Strasbourg

Natural Biased-ligands: A Classical Tine-tuner of GPCR Physiology? Example of the Renin-Angiotensin-Aldosterone System
Céline GALES, Université Paul Sabatier, Toulouse, France

Allosteric Regulation of TGFß Type I Receptor by the Orphan GPR50 – an Alternative Way to Define the Function of Orphan GPCRs
Ralf Jockers, Institut Cochin, Paris, Inserm U1016, CNRS 8104, Université Paris Descartes

From Receptors to Ligands: Evotec’s Integrated Pipeline for GPCR Structure-Based Drug Discovery
Dr Constantino Diaz, Evotec (France) SAS

Linking the Mast Cell Receptor, Mrgprx2, to Adverse Histamine-like Reactions in vivo, in Preclinical Drug Development
Andrew Brown, GSK, Molecular Discovery Research

Using Phenotypic Assays to Explore EP4 Receptor Agonism in Airway Remodeling
Dr Elizabeth M Rosethorne, Snr Research Fellow, University of Nottingham

Identification of Endogenous and Surrogate Ligands for Orphan GPCRs – Through Computational Drug Design Methods
David Gloriam, Associate Professor, Department of Drug Design and Pharmacology, University of Copenhagen